Ingrezza (valbenazine) is a medication used to treat tardive dyskinesia (TD) and chorea associated with Huntington’s disease. These conditions cause involuntary movements like twitching, jerking, or ...

Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label ...

THIS report describes the clinical, laboratory and genetic investigations of a large Negro family, many of whose members exhibit choreiform movements of early onset and nonprogressive nature. As far ...

A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 ...

People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

An alternate, unitary explanation of these findings was suggested by a previous study from this hospital. 7 Data were presented showing that when chorea, rheumatic polyarthritis and carditis occur in ...

Medically reviewed by Huma Sheikh, MD Key Takeaways The medications approved by the Food and Drug Administration (FDA) for ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves chorea, a ...

Chorea gravidarum is uncommon movement disorder of pregnancy, characterized by involuntary, abrupt, non-rhythmic movements. It can be idiopathic or secondary to the underlying pathology. A 28-year-old ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

Please provide your email address to receive an email when new articles are posted on . Most patients with chorea and antiphospholipid antibody were women, with chorea onset at an average age of 22.8 ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...